Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739411 · ClinicalTrials.gov registry record · Phase 1
Hyperpolarized Imaging in Diagnosing Participants With Glioma
A Phase 1 study of Glioma, sponsored by Susan Chang.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT03739411: Recruiting Phase 1 study of Glioma, sponsored by Susan Chang.
NCT03739411 is a Phase 1 study of Glioma that is actively recruiting participants, run by Susan Chang. The registered enrollment target is 140 participants, below the 208-participant average among 87 other Glioma trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03739411, a Phase 1 study of Glioma, is actively recruiting participants, sponsored by Susan Chang.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Primary Outcome
Adverse events will be monitored from just before investigational medicinal product (IMP) administration until the end of study participation. Vital signs (blood pressure and heart rate only) will be recorded at baseline and 30 minutes post injection. For blood pressures and heart rate recorded after IMP administration, the following safety endpoints will be summarized for each part of the study: (1) The occurrence of changes from baseline, at each post-administration time point, greater than a
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Radiation Therapy
- DRUG Chemotherapy
- RADIATION Hyperpolarized Carbon C 13 Pyruvate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-12-09 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 1 |
What NCT03739411 shows while recruiting
NCT03739411 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 208-participant average among 87 other Glioma trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 4 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT03739411 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03739411 about?
NCT03739411 is a clinical study titled "Hyperpolarized Imaging in Diagnosing Participants With Glioma". This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
What is the current status of trial NCT03739411?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2015-12-09. Estimated completion is 2028-06-01.
What conditions does trial NCT03739411 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT03739411?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Chemotherapy (DRUG), Hyperpolarized Carbon C 13 Pyruvate (RADIATION).
Who is sponsoring clinical trial NCT03739411?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739411 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03739411's enrollment target sits among peer trials
140 12th of 87 higher than 76 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI